Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Friday

Key Points

• Tonix Pharmaceuticals is expected to announce its Q1 2025 earnings on August 15th, projecting a loss of ($6.71) per share with $2.60 million in revenue.
• The company recently reported a quarterly loss of ($2.84) EPS, beating estimates, but had a significantly negative return on equity of 120.96%.
• Insider CEO Seth Lederman purchased 4,000 shares at $21.55 each, significantly increasing his ownership stake as institutional investors hold 82.26% of the stock.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Friday, August 15th. Analysts expect the company to announce earnings of ($6.71) per share and revenue of $2.60 million for the quarter.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($2.84) EPS for the quarter, topping analysts' consensus estimates of ($3.23) by $0.39. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 120.96% and a negative net margin of 1,313.87%. On average, analysts expect Tonix Pharmaceuticals to post $-1,763 EPS for the current fiscal year and $-542 EPS for the next fiscal year.

Tonix Pharmaceuticals Trading Up 1.8%

Shares of Tonix Pharmaceuticals stock traded up $0.82 during trading hours on Monday, reaching $47.31. The stock had a trading volume of 174,306 shares, compared to its average volume of 1,300,216. The firm has a 50 day simple moving average of $39.76 and a two-hundred day simple moving average of $26.68. The firm has a market capitalization of $348.22 million, a price-to-earnings ratio of -0.02 and a beta of 1.70. Tonix Pharmaceuticals has a 1 year low of $6.76 and a 1 year high of $130.00.

Insider Activity

In related news, CEO Seth Lederman bought 4,000 shares of the stock in a transaction dated Thursday, May 15th. The stock was acquired at an average price of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the purchase, the chief executive officer owned 4,005 shares in the company, valued at $86,307.75. This represents a 80,000.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.03% of the company's stock.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Royal Bank of Canada acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 34,153 shares of the company's stock, valued at approximately $610,000. Royal Bank of Canada owned approximately 0.53% of Tonix Pharmaceuticals as of its most recent SEC filing. 82.26% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TNXP. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Alliance Global Partners reiterated a "buy" rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, June 3rd.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.